Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
28,650
datasets available to search
ShareScore release 0.9.0
Dataset results
28,650 results for “trial”
Data from randomized control trials released hatchery salmon treated with anti-parasitic treatment
<p>Data used in the article "<strong>Parasite spillback from fish farms reduce return rate of wild salmon"</strong></p> <p> </p> <p>Each release group has been used as a randomized control trials (RCT) of hatchery reared salmon smolts where half of the fish has been treated with an antiparasitic drug. Description of this method has been given in various other publications (Vollset et al. 2014, Vollset et al 2016, Skilbrei et al. 2013). The method involves rearing salmon eggs originating from the national Gene Bank to smolt size in hatchery facilities during one year, and then treating the salmon smolts with fish feed pellets coated with emamectin benzoate (SLICE®). These fish are then released into the river or transported in tanks or mobile net pens further out in the fjord before release. The fish are tagged with either coded-wire-tags (CWT; years 2000-2017) or Passive Integrated Transponders (PIT; 2015-2019) so that it is possible to identify them as they are recaptured or registered on an antenna upon their return as adults. In a few trials, another antiparasitic treatment (Substance EX) has been used, but in most cases the EB has been the only available treatment. Releases of hatchery reared salmon in freshwater have not been successful in this system, i.e. very few fish have returned from any group released in the river, lakes or estuary of Vosso. Since the release groups are also a part of a restoration effort of the Vosso salmon, some years fish have only been released in the fjord. There has been some variation in the release sites in the fjords, but for the purpose of this study we group the release groups in either group that has been released in the outer fjord (70-105 km from the river mouth) and the inner fjord (15-70 km from the river mouth), and freshwater (approx -10 to 15 km from the river mouth). The two most prevalent locations are at Manger (WGS84; 60.63918, 4.92149) and Arna (WGS84; 60.50812, 5.37777).</p> <p> </p> <p><em>Sea lice surveillance</em></p> <p> </p> <p>Sea lice surveillance on sea trout has been conducted at Herdla, the northern peninsula of the island Askøy (WGS84; 60.568972, 4.963010) since 2009. Here, trout have been caught using a trap net that has been developed specifically to capture and treat trout while minimizing sea lice loss during handling (Barlup et al. 2013). From an earlier study by Vollset et al. (2018), it has been shown that the lice numbers on sea trout on this site correlate with the infestation pressure of fish farms in the outer region of the fjord. This area is also one of the largest fish farm zones with coordinated production and fallowing in the outer fjord system where all the released salmon smolts must migrate (see Vollset et al. 2018). This is also the area where surface salinity layers permit salmon lice to overlap with out-migrating salmon smolts (Vollset et al. 2016).</p> <p> </p> <p>The number of trout caught during the monitoring season has varied with weather conditions, sampling intensity, and number of traps operated. The way that trout are handled is described in more detail in Vollset et al. (2018), but in brief, the trap chambers are checked daily, and individual trout are transferred from the trap using a hand held dip net and are either euthanized and placed in zip-lock bag or transported in a large bucket with aerated water to land. Euthanized samples are kept cold and frozen when at land, and later thawed and counted in the lab, while live samples are counted after being sedated with half dose (0.05 g/L) of MS222 and then assessed for salmon lice in a high-contrast bucket using a headlamp by trained personnel. Since 2015 the sea lice surveillance at Herdla is also operated as a part of the Norwegian national sea lice monitoring program.</p> <p>We aimed to use a standardized time period from which to assess sea lice numbers on sea trout that can be representative of the lice infestation pressure from when the tagged hatchery salmon smolts are released. When counting sea lice on sea trout, the most observable lice are large chalimus and mobile stages, while recently attached copepods are more likely to be missed. Therefore, we use total lice counts on sea trout from Julian day 135 to 165 as an assessment of the infestation pressure the salmon smolts must experience. This corresponds to approximately 15 May to 15 of June, and is based on a study on progression rate of salmon smolts from hatchery smolt in this area (Vollset et al. 2016). To account for the fact that larger fish will attract more parasites, we use parasites per gram fish per individual and average data to get one index per year. This method is expected to provide a fair index of interannual variation of the infestation pressure.</p> <p> </p> <p>Table 1 Description of column names in csv file</p> <table> <tbody> <tr> <td>Name</td> <td>Description</td> </tr> <tr> <td>release_year</td> <td>Year of release as smolts</td> </tr> <tr> <td>release_place</td> <td>Name of release place location</td> </tr> <tr> <td>release_date</td> <td>Date of release as smolts</td> </tr> <tr> <td>Released</td> <td>Number of hatchery smolt released</td> </tr> <tr> <td>Recaptured</td> <td>Number of hatchery smolt recaptured as adults</td> </tr> <tr> <td>treat</td> <td>Treatment (either treatment or control)</td> </tr> <tr> <td>tag</td> <td>Tag type (either CWT or PIT)</td> </tr> <tr> <td>release_category</td> <td>Release place (either river, outer fjord or inner fjord)</td> </tr> <tr> <td>lpg</td> <td>Lice per gram fish on trout during surveillance from 15 of May to 15 of June the year of release</td> </tr> <tr> <td>pr</td> <td>Percent (%) recaptures as adults</td> </tr> </tbody> </table> <p> </p>
Monitoring feedback to authors on the quality of trials evaluating interventions aimed at preventing and treating COVID-19
<p>We aimed to assess transparency of reporting and risk of bias of randomized trials evaluating interventions aimed at preventing and treating COVID-19.</p> <p>This review is part of a larger project: the COVID-NMA project (Boutron 2020a). The COVID-NMA project aims to provide decision-makers with a complete, high-quality and up-to-date synthesis of evidence on interventions for the prevention and treatment of COVID 19. For this purpose, we perform a living mapping of all registered randomized controlled trials and a living evidence synthesis of data from RCTs. We developed a master protocol on the effect of all interventions for the prevention and treatment of COVID-19 (first published on April 8, 2020; an update on May 11, 2020, June 17, 2020, and September 8, 2020) (Boutron 2020b). We set-up a platform (<a href="https://covid-nma.com/">https://covid-nma.com</a>) where all our results are made available and updated weekly.</p>
Global Trends in Clinical Trials Involving Engineered Biomaterials
<p><span>The study aimed to conduct a comprehensive analysis of all clinical trials involving engineered biomaterials by utilizing the ClinicalTrials.gov database. The search was executed in August 2023, and the analysis encompassed various attributes of the included studies, including the study title, URL, target disease, condition, intervention, biomaterial category, biomaterial type, specific biomaterial used, biomaterial properties, incorporation of cells, participant age and gender, clinical study phase, enrollment figures, study location, and the study's start and end dates. The corresponding data was systematically collected from the included studies and organized into dataset </span><span>(</span><span>Dataset </span><span>S1 and </span><span>Dataset </span><span>S2).</span></p>
Data and analysis supplement for: Functional imagery training versus motivational interviewing for weight loss: a randomised controlled trial of brief individual interventions for overweight and obesity.
<p>This submission provides the data and code for analyses reported in our publication.</p>
Feeding trials of Leptagrion andromache and prey species
<p>We quantified the consumption rate for one damselfly larvae predator and many of its prey. The top predator Leptagrion andromache (Zygoptera: Odonata, dry mass = 3.31 mg, se = 2.45, n = 29) was fed several densities of each prey. The prey were chosen because they were the most abundant prey in bromeliads. All prey are aquatic insect larvae. We chose Culex sp 1 (Culicidae: Diptera, density range = 1- 50, mean dry mass = 0.17 mg, se = 0.04, n = 25), Culex sp 2 (Culicidae: Diptera, 1-20, 0.09 mg, 0.02, 14), Forcipomyia (Ceratopogonidae: Diptera, 1-60, 0.07 mg, 0.01, 5), Dero superterrenus (Naididae: Haplotaxida, 1-60, 0.12 mg, 0.01, 2), Psychodidae (Psychodidae: Diptera, 1-30, 0.22 mg, 0.11, 18), Scirtes sp 1 (Scirtidae: Coleoptera, 1-30, 0.33 mg, 0.12, 13), Scirtes sp 2 (Scirtidae: Coleoptera, 1-6, 0.43 mg, 0.27, 65), and Trentepohlia (Tipulidae: Diptera, 1-7, 0.29 mg, 0.19, 43).</p>
Data and supplementary files of the publication: "What Goes Around Should Not Move Around: Immobilizing Microplastics as a New Approach for Analytical Ring Trials"
<p>Accompanying materials for the publication: <a href="https://doi.org/10.1021/acs.est.4c09427">https://doi.org/10.1021/acs.est.4c09427</a></p>
S120 | DUSTCT2024 | Substances from Second NORMAN Collaborative Dust Trial
<p>This is the collection associated with list S120 DUSTCT2024 Substances from Second NORMAN Collaborative Dust Trial on the NORMAN Suspect List Exchange.</p> <p><a href="https://www.norman-network.com/nds/SLE/">https://www.norman-network.com/nds/SLE/</a></p> <p>List of substances detected via GC-MS and LC-MS from the second NORMAN collaborative dust trial initiated in 2020, including classification and detection information as described in Haglund et al (2024) DOI: <a href="https://doi.org/10.1016/j.scitotenv.2024.177639">10.1016/j.scitotenv.2024.177639</a>. </p> <p> </p>
CT-EBM-SP - Corpus of Clinical Trials for Evidence-Based-Medicine in Spanish (version 2)
<p>A collection of <strong>1200 texts</strong> (292173 tokens) about<strong> clinical trials studies</strong> and <strong>clinical trials announcements</strong> in <strong>Spanish</strong>:</p> <p>- 500 abstracts from journals published under a Creative Commons license, e.g. available in PubMed or the Scientific Electronic Library Online (SciELO).<br>- 700 clinical trials announcements published in the European Clinical Trials Register and Repositorio Español de Estudios Clínicos.</p> <p>Texts were annotated with the following entities types:</p> <p>- <strong>Semantic groups from the Unified Medical Language System</strong>: <br> • ANAT: anatomy<br> • CHEM: pharmacological and chemical substances<br> • DEVI: medical devices<br> • DISO: pathologic conditions <br> • LIVB: living beings, included the human being<br> • PHYS: physiological processes<br> • PROC: lab tests, diagnostic or therapeutic procedures<br>- <strong>Medical drug information</strong>:<br> • Contraindicated: a contraindicated drug or treatment<br> • Dose: dose or strength<br> • Form: dosage form<br> • Route: administration route or mode<br>- <strong>Temporal expressions</strong> <br> • Age<br> • Date<br> • Duration<br> • Frequency<br> • Time<br>- <strong>Miscellaneous medical entities</strong>: <br> • Concept: abstract concepts, statistical tests or measurement scales<br> • Food: foods or drinks<br> • Observation: medical observations or clinical findings<br> • Quantifier_or_Qualifier: quantifier or qualifier adjective<br> • Result_or_Value: result or value of a measurement, laboratory analysis or procedure<br>- <strong>Negation/Speculation</strong>: <br> • Neg_cue: negation cue<br> • Negated: negated event<br> • Spec_cue: speculation cue<br> • Speculated: speculated or uncertain event<br>- <strong>Attributes</strong>: <br> • Temporality:<br> ◦ History_of: past event<br> ◦ Future: future event<br> • Experiencer:<br> ◦ Patient: patient or participant on a clinical trial<br> ◦ Family_member<br> ◦ Other: other person different from the patient or the family member</p> <p>86 389 entities and 16 590 attributes were annotated. 10% of the corpus was doubly annotated, and high inter-annotator agreement (IAA) values were achieved: F1-score = 0.84% for entities; and F1-score = 0.88% for attributes (both in strict match). </p> <p>The dataset includes the <strong>texts and annotations used for the human evaluation</strong> of the medical named entity tool:</p> <p>- 100 clinical trial announcements from EudraCT not used for system development: we provide files of the version revised by medical professionals (Reference folder)<br>- 100 clinical cases with Creative Commons license: we provide files with the files revised by medical professionals (Reference folder). These data come from:</p> <p> • Urgencias Bidasoa (https://urgenciasbidasoa.wordpress.com/casos-clinicos-3/)<br> • Hipocampo.org (https://www.hipocampo.org/)<br> • Cases published by Sociedad Andaluza de Medicina Familiar y Comunitaria (SAMFyC): we are greatly thankful for giving us permission to use these cases and we acknowledge that the copyright belongs to the authors' contents. Clinical cases were extracted from books published from 2016 to 2022 (https://www.samfyc.es/tipos-publicacion/publicaciones/).<br> <br>If you use these data, please, acknowledge the copyright and intellectual property rights to the authors' contents.</p> <p>The dataset is freely distributed for research and educational purposes under a Creative Commons Non-Commercial Attribution (CC-BY-NC-A) License.</p> <p>If you use the CT-EBM-SP vs. 2 dataset, please, cite as follows:</p> <p>Campillos-Llanos, L., A. Valverde-Mateos & A. Capllonch-Carrion (2024) Hybrid natural language processing tool for semantic annotation of medical texts in Spanish. BMC Bioinformatics. BioMed Central.</p>
Reference sheet for the dataset: BioCam ALR PLOCAN Trials (03/14/2024 – 03/16/2024)
<p>This reference document provides a brief description of the data and a link to the full data repository, which includes mapping and imagery data.</p> <p>For further information, please email <span><a href="mailto:adrian.bodenmann@soton.ac.uk">adrian.bodenmann@soton.ac.uk</a> or <a href="mailto:comms.techoceans@aquatt.ie">comms.techoceans@aquatt.ie</a>.</span></p>
Protein tagged from Covid-19 trial records in ClinicalTrials.gov
<p>Top 200 proteins appeared in the Covid-19 trial records in https://clinicaltrials.gov/, grouped by CATH classification, with URL linking back to the trial record at https://clinicaltrials.gov/.</p>
Dron view of the 2021 field trial for BRESOV project in SERIDA
<p>This video shows the field trial with 311 snap bean lines in organic conditions.</p> <p>The field trial had three plots per line with ten plants distributed in 1 m.</p> <p>This wide diversity is being evaluated considering morpho-agronomic characters.</p> <p>This work is part of the BRESOV project funded by the EU (Grant agreement ID: 774244 ).</p> <p>This video was recorded at the SERIDA facilities, Villaviciosa, Asturias, Spain in July 2021.</p> <p>DOI 10.5281/zenodo.5573917</p> <p><strong>Also available in the link: </strong> https://www.youtube.com/watch?v=dJa9UDFQnOE&t=5s</p>
An Audibility Model of the Bone Conduction Device during Headband Trial in Single-sided Deaf Subjects.
<p><strong>Data of the study, including primary data, calculated data, analysis results and graphs.</strong></p> <p><strong>Related software</strong><br> <a href="https://doi.org/10.5281/zenodo.7295482">zenodo.7295482</a></p> <p><strong>Abstract<br> Objective</strong><br> Modelling the head-shadow-effect compensation and speech intelligibility outcomes, we studied the benefits of fitting a bone conduction device (BCD) during the headband trial in single-sided deafened (SSD) subjects.</p> <p><strong>Design</strong><br> The participants’ BCD settings were retrospectively used for measurements on the skull simulator. The sensation levels of the Bone-Conduction and Air-Conduction sound paths were compared, modelling three spatial conditions with the speech in quiet. When the difference between sensation levels was equivalent or greater than zero, this was scored as full head-shadow-effect compensation. We calculated the phoneme score using the Speech Intelligibility Index for the three conditions in quiet and seven in noise.</p> <p><strong>Study sample</strong><br> Data from eighty-five SSD adults fitted with a BCD during the headband trial.</p> <p><strong>Results</strong><br> According to our model, most subjects did not achieve a full head-shadow-effect compensation with the signal at the BCD side and in front. The modelled speech intelligibility in the quiet condition did not improve with the transcutaneous BCD compared with the unaided condition. In noise, we found a slight improvement in some specific conditions and minimal worsening in others.</p> <p><strong>Conclusions</strong><br> Based on an audibility model, this study challenges the fundamentals of a trial period with a transcutaneous BCD in SSD subjects.</p> <p> </p>
Witchcraft trials in the Czech lands: Data on persons, places, charges, punishments, and material substances
<p>This is the most comprehensive digital dataset of witchcraft trials in the Czech lands since the earliest case in 1491 until as late as 1785. The dataset covers 257 cases. It records the year, the suspects' names, their sex, places of residence (including geographic coordinates), charges, results of the trial, places of interrogation (including geographic coordinates), and the material substances they were charged of using to perform magic. The dataset allows researchers to conduct systematic and quantitative research into early modern withcraft trials, crime and punishment, as well as the imagery of magic and evil-doing. It also allows to include the Czech lands in broader quantitative studies of European witchcraft trials on a large temporal and geographic scale. Five B.A. theses have been written at Masaryk University, Brno, Czech Republic on the basis of this dataset.</p> <p>The dataset does not cover all known trials. Based on data availability, we did our best to cover what was published and reasonably accessible, but we did not perform original archival research. Our very rough estimate is that up to 100 further specific witchcraft trials in the Czech lands could be identified in published material, and archival work could reveal further ca. 250-800 cases.</p>
Data for Project 'Feasibility, Usability and Acceptance of a Newly Developed Exergame-Based Training Concept for Older Adults with Mild Neurocognitive Disorder - A Pilot Randomized Controlled Trial'
<p>Data for Project 'Feasibility, Usability and Acceptance of a Newly Developed Exergame-Based Training Concept for Older Adults with Mild Neurocognitive Disorder - A Pilot Randomized Controlled Trial' (trial registered at clinicaltrials.gov (<a href="https://clinicaltrials.gov/ct2/show/NCT04996654">NCT04996654</a>; date of registration: 11 July 2021), consisting of:</p> <p>(1) the original and complete data set for all primary outcomes ('Data_Primary-Outcomes_Brain-IT-Pilot-Feasibility-RCT_for-publication.xlsx');</p> <p>(2) the original and complete data set for all secondary outcomes ('Data_Secondary-Outcomes_Brain-IT-Pilot-Feasibility-RCT_for-publication.xlsx');</p> <p>(3) the original and complete data set for all other outcomes (i.e. baseline factors (demographic data, type of usual care interventions) and training heart rate; 'Data_Other-Outcomes_Brain-IT-Pilot-Feasibility-RCT_for-publication.xlsx');</p> <p>(4) folder including the raw and processed heart rate variability (HRV) and electroencephalography (EEG) data for all participants and measurements (HRV-and-EEG_raw-and-processed-data.zip);</p> <p>(5) a corresponding README file including (a) general information, (b) data and file overview, (c) sharing and access information, (d) methodological information, and (e) data-specific information.</p>
Dataset of Pro health field trial against the monogenean Sparicotyle chrysophrii
<p>Dataset of parasitological data collected during a field trial on functional feed to limit the impact of Sparicotyle chrysophrii on farmed gilthead sea bream (Sparus aurata)</p>
Eurex-LUNa Abisko Trials Lawnmower Waypoints
<p>Navigation data of the AUV DeepLeng during field trials in an ice-covered lake in Abisko, Sweden.</p> <p>For more information on this field trials: <a href="https://www.dfki.de/web/forschung/eurex-abisko">https://www.dfki.de/web/forschung/eurex-abisko</a></p> <p>This dataset is described in the paper</p> <p>M. Hildebrandt, T. Creutz, B. Wehbe, M. Wirtz and M. Zipper, "Under-Ice Field tests with an AUV in Abisko/Torneträsk," OCEANS 2022, Hampton Roads, Hampton Roads, VA, USA, 2022, pp. 1-7, doi: 10.1109/OCEANS47191.2022.9977094.</p> <p>For more details on how to use the data files, please refer to the Readme.md</p> <p>Contact: tom.creutz@dfki.de, bilal.wehbe@dfki.de</p> <p> </p> <p><em>Disclaimer:</em></p> <p>The stereo camera images are not intrinsically and extrinsically calibrated. Please use the dataset provided under DOI 10.5281/zenodo.7274517 .</p> <p> </p> <p>Funded by BMWi (Kennziffer 50 NA 2002)</p>
Eurex-LUNa Abisko Trials Rectangle Waypoints
<p>Navigation data of the AUV DeepLeng during field trials in an ice-covered lake in Abisko, Sweden.</p> <p>For more information on this field trials: <a href="https://www.dfki.de/web/forschung/eurex-abisko">https://www.dfki.de/web/forschung/eurex-abisko</a></p> <p>This dataset is described in the paper</p> <p>M. Hildebrandt, T. Creutz, B. Wehbe, M. Wirtz and M. Zipper, "Under-Ice Field tests with an AUV in Abisko/Torneträsk," OCEANS 2022, Hampton Roads, Hampton Roads, VA, USA, 2022, pp. 1-7, doi: 10.1109/OCEANS47191.2022.9977094.</p> <p>For more details on how to use the data files, please refer to the Readme.md</p> <p>Contact: tom.creutz@dfki.de, bilal.wehbe@dfki.de</p> <p><br> Funded by BMWi (Kennziffer 50 NA 2002)</p>
Dataset and codebook for the article by Gaume J, Bertholet N, McCambridge J, et al. Effect of a Novel Brief Motivational Intervention for Alcohol-Intoxicated Young Adults in the Emergency Department: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(10):e2237563. doi: 10.1001/jamanetworkopen.2022.37563
<p>Dataset and codebook for the article Gaume J, Bertholet N, McCambridge J, et al. <strong>Effect of a Novel Brief Motivational Intervention for Alcohol-Intoxicated Young Adults in the Emergency Department: A Randomized Clinical Trial</strong>. JAMA Netw Open. 2022;5(10):e2237563. doi: <a href="http://jamanetwork.com/article.aspx?doi=10.1001/jamanetworkopen.2022.37563">10.1001/jamanetworkopen.2022.37563</a></p> <p>The dataset contains all data needed to reproduce the results in the above cited article.</p> <p>Variable description and labels can be found in the codebook.</p> <p>Please refer to the published article and supplemental online content for further information about the data and the study procedures.</p>
Tea bag index (TBI) for a pot trial with five plant species in Trani (Apulia, Italy)
<p>The file contains mean k and S value per GPS location, with as meta-data the starting date, duration and biome of the study.</p>
Geographic Scope of Randomized Clinical Trials from Africa
<p><strong>Overview</strong></p> <p>This map reports the geographic scope of randomized controlled trials (RCTs) conducted in Africa, as found in PubMed. The map highlights a discrepancy between actual trial location and how trials are reported: although reports of research from Africa are often labeled as being "African" in scope, RCTs are rarely continent-wide and many countries are not represented in even a single study. The intent of the map is to visualize actual trial locations, hopefully leading to a more accurate portrayal of RCT study sites on the African continent.</p> <p><strong>Data Source and Tools</strong></p> <p>Data for the map was extracted from PubMed and the map was created in ArcGIS Online.</p> <p><strong>Audience</strong></p> <p>The map was created for an original research poster at the 2022 International Congress on Peer Review and Scientific Publication (see "Attribution" below). Its audience is researchers, clinicians, policy makers, librarians, scholarly communications stakeholders, and editors in chief interested in improving the accuracy of the reported scope of research in Africa to better inform health care research, policy, and resource distribution.</p> <p><strong>Design</strong></p> <p>A PubMed search using Medical Subject Headings and keywords representing Africa, African, and RCTs was run to identify citations published between 1968 and February 2022. The citation titles and abstracts were screened against established inclusion/exclusion criteria, with included studies continuing through a full text review and data extraction process. Total RCT representation per country was then mapped in ArcGIS with higher RCT counts represented by darker shading. The map highlights the variance in RCT representation across the continent, with some countries represented in up to 80 RCTs and many countries represented in none.</p> <p><strong>Attribution</strong></p> <p>Folafoluwa Olutobi Odetola and Marisa L. Conte conceived the research question, crafted the PubMed search, and analyzed the citation data; Tyler Nix created the map. Special thanks to Caroline Kayko (University of Michigan) for her input in the creation of the map. </p> <p>See the original research poster at:</p> <p>Odetola, FO; Conte, ML. Geographical Scope of Randomized Clinical Trials from Africa. [Poster]. 9th International Congress on Peer Review and Scientific Publication, September 8-10, 2022, Chicago, IL. Available from: <a href="https://peerreviewcongress.org/abstract/geographical-scope-of-randomized-clinical-trials-from-africa/">https://peerreviewcongress.org/abstract/geographical-scope-of-randomized-clinical-trials-from-africa/</a></p> <p>The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.